Amarin Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Pfizer, BioNTech Initiates Study Of Omicron-Based Vaccine Candidate Pfizer, Inc. (NYSE: PFE) and BioNT

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.

Amarin Corporation plc (AMRN) CEO Karim Mikhail Presents at 40th Annual J.P. Morgan Healthcare Conference (Transcript)

Amarin (AMRN) provides a business update, including preliminary full-year 2021 revenue results. Q4 and FY 2021 total net revenues are estimated to be ~$140M (consensus $156.02M)

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is s

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQGM: AMRN)

Analysts expect that Amarin Co. plc (NASDAQ:AMRN) will report $159.26 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Amarins earnings, with the highest sales estimate coming in at $192.80 million and the lowest estimate coming in at $139.60 million. Amarin reported sales of $167.25 million [] The post Brokerages Anticipate Amarin Co. plc (NASDAQ:AMRN) Will Post Quarterly Sales of $159.26 Million appeared first on ETF Daily News .

NEW YORK, Dec. 21, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation PLC ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers. The class action, filed in the United States District Court for the District of

NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Friday, December 17th by Pomerantz LLP, please note that in the second paragraph, the lead plaintiff deadline has been updated from December 21, 2021 to December 23, 2021. The corrected release follows:

Shares of Amarin Co. plc (NASDAQ:AMRN) have been assigned a consensus rating of Buy from the six brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 12 month []

NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amarin Corporation plc (Amarin or the Company) (NASDAQ: AMRN) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-19911, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Amarin securities between December 5, 2018 and June 21, 2021, inclusive (the Class Period), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act) and Rule 10b-5 promulgated thereunder by the Securities and Exchange Commission.

Amarin Co. plc (NASDAQ:AMRN) Director Joseph S. Zakrzewski purchased 10,000 shares of the firms stock in a transaction that occurred on Tuesday, December 14th. The stock was purchased at an average price of $3.27 per share, with a total value of $32,700.00. The purchase was disclosed in a document filed with the Securities & Exchange []

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021, inclusive (the Class Period) of the important December 23, 2021 lead plaintiff deadline .